Related trials
JUPITER, 2008 - rosuvastatin vs placebo
Song, 2008 - vs
SAGE, 2007 - atorvastatin high dose vs pravastatin
METEOR, 2007 - rosuvastatin vs placebo
CORONA, 2007 - rosuvastatin vs placebo
Chello et al., 2006 - preoperative atorvastatin vs placebo
ASPEN, 2006 - atorvastatin vs placebo
SPARCL, 2006 - atorvastatin vs placebo
Patti et al., 2006 - preoperative atorvastatin vs placebo
MEGA, 2006 - pravastatin vs control
IDEAL, 2005 - atorvastatin high dose vs simvastatin
Vascular basis, 2005 - atorvastatin high dose vs lovastatin
TNT, 2005 - atorvastatin high dose vs atorvastatin
PACT, 2004 - pravastatin vs placebo
A to Z, 2004 - simvastatin vs placebo
ESTABLISH, 2004 - atorvastatin vs usual care
REVERSAL, 2004 - atorvastatin high dose vs pravastatin
HPS (sub groups), 2004 - simvastatin vs placebo
CARDS, 2004 - atorvastatin vs placebo
PACT, 2004 - pravastatin vs placebo
ASCOT, 2003 - atorvastatin vs placebo
LIPS (sub groups), 2002 - fluvastatin vs placebo
ALLHAT, 2002 - pravastatin vs usual care
PTT, 2002 - pravastatin vs usual care
PROSPER, 2002 - pravastatin vs placebo
See also:
All CABG surgery clinical trials
All clinical trials of cholesterol lowering intervention
All clinical trials of preoperative atorvastatin
|
|
Treatments
Studied treatment |
preoperative atorvastatin 20 mg/d, started 3 wks before surgery
|
Control treatment |
placebo
|
Patients
Method and design
Randomized effectives |
20 / 20 (studied vs. control) |
Blinding |
double blind |
Follow-up duration |
7 days |
Results
Endpoint
Studied treat. n/N
Control treat. n/N
Graph
RR [95% CI]
atrial fibrillation
2 / 20
5 / 20
0,40 [0,09;1,83]
myocardial infarction (fatal and non fatal)
0 / 20
0 / 20
classic
1,00 [0,00;246,89]
All cause death
0 / 20
0 / 20
classic
1,00 [0,00;246,89]
stroke (fatal and non fatal)
0 / 20
0 / 20
classic
1,00 [0,00;246,89]
0
2
1.0
Relative risks
|
Endpoint |
Events (%) |
Relative Risk |
95% CI |
Endpoint definition in the trial |
Ref |
Studied treat. |
Control treat. |
atrial fibrillation
|
2 / 20 (10,0%) |
5 / 20 (25,0%) |
0,40 |
[0,09;1,83] |
|
|
myocardial infarction (fatal and non fatal)
|
0 / 20 (2,5%) |
0 / 20 (2,5%) |
1,00 |
[0,02;47,98] |
|
|
All cause death
|
0 / 20 (2,5%) |
0 / 20 (2,5%) |
1,00 |
[0,02;47,98] |
|
|
stroke (fatal and non fatal)
|
0 / 20 (2,5%) |
0 / 20 (2,5%) |
1,00 |
[0,02;47,98] |
|
|
The primary endpoint (if exists) appears in blod characters
|
Reference(s) used for data extraction:
0:
|
Endpoint |
studied treat. |
control treat. |
mean diff |
Absolute risk reduction (for a follow-up of 7 days)
|
Endpoint |
Events rate |
Absolute risk reduction (ARR) |
Studied treat. |
Control treat. |
atrial fibrillation |
10,00% |
25,00% |
-15,00%
|
Meta-analysis of all similar trials:
cholesterol lowering intervention in CABG surgery for preoperative statins
Reference(s)
TrialResults-center ID |
TRC7245
|
Trials register # |
NA
|
-
Chello M, Patti G, Candura D, Mastrobuoni S, Di Sciascio G, Agr� F, Carassiti M, Covino E.
Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery..
Crit Care Med 2006;34:660-7
Pubmed
|
Hubmed
| Fulltext
|